Comparative Pharmacology
Head-to-head clinical analysis: BETAPAR versus CORTIFOAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAPAR versus CORTIFOAM.
BETAPAR vs CORTIFOAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist that stimulates adenylyl cyclase, increasing cAMP levels, leading to bronchodilation.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
Initial: 25 mg orally twice daily; may increase gradually to 100 mg twice daily based on tolerance and response.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
None Documented
None Documented
Terminal elimination half-life is 3-5 hours in patients with normal renal function; prolonged to 10-20 hours in severe renal impairment (CrCl <30 mL/min).
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%; the remainder undergoes hepatic metabolism.
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
Category C
Category C
Corticosteroid
Corticosteroid